More Work Will Be Needed to Harness the Full Potential of Patient Reported Outcomes Measurements
December 18th 2023Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital, also gave his thoughts on the recent FDA approval of Vertex and CRISPR’s exa-cel for sickle cell disease.
Veit Bücklein, Dr Med, on CAR-T Outcomes Between Male and Female Patients With LBCL
December 16th 2023The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed the need for research into how CAR T-cells act differently between sexes.
Steven W. Pipe, MD, on Data Continuing to Support Etranacogene Dezaparvovec Over SOC in Hemophilia B
December 12th 2023The professor of pediatric hematology/oncology at CS Mott Children’s Hospital discussed 3-year follow-up data from the HOPE B trial of the approved gene therapy, branded as Hemgenix.
Liso-cel Shows Continued Durability in Long-Term Follow-Up Data of r/r CLL/SLL
December 11th 2023Among patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, the Bristol Myers Squibb CAR T cell product showed consistent efficacy in patients with a lack of success with BTK inhibitor and venetoclax treatment.
Colleen E. Annesley, MD, on Working to Mitigate Inferior Cell Persistence With Manufactured T-APCs
December 11th 2023The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.